10 results on '"Nam, Soo‐Hyun"'
Search Results
2. Neural cell adhesion molecule 1 is a cellular target engaged plasma biomarker in demyelinating Charcot–Marie–Tooth disease.
- Author
-
Kim, Young Hee, Yoon, Byeol‐A, Jo, Young Rae, Nam, Soo Hyun, Kim, Nam Hee, Kim, Kyoung Hee, Kim, Jong Kuk, Choi, Byung‐Ok, and Park, Hwan Tae
- Subjects
NEURAL cell adhesion molecule ,CHARCOT-Marie-Tooth disease ,DEMYELINATION ,CELL adhesion molecules ,NEUROTROPHINS ,NEUROTROPHIN receptors ,ENZYME-linked immunosorbent assay ,MYELIN sheath diseases - Abstract
Background and purpose: Elevated plasma concentrations of neural cell adhesion molecule 1 (NCAM1) and p75 neurotrophin receptor (p75) in patients with peripheral neuropathy have been reported. This study aimed to determine the specificity of plasma concentration elevation of either NCAM1 or p75 in a subtype of Charcot–Marie–Tooth disease (CMT) and its correlation with pathologic nerve status and disease severity. Methods: Blood samples were collected from 138 patients with inherited peripheral neuropathy and 51 healthy controls. Disease severity was measured using Charcot–Marie–Tooth Neuropathy Score version 2 (CMTNSv2), and plasma concentrations of NCAM1 and p75 were analyzed by enzyme‐linked immunosorbent assay. Eight sural nerves from CMT patients were examined to determine the relation of histopathology and plasma NCAM1 levels. Results: Plasma concentration of NCAM1, but not p75, was specifically increased in demyelinating subtypes of CMT (median = 7100 pg/mL, p < 0.001), including CMT1A, but not in axonal subtype (5964 pg/mL, p > 0.05), compared to the control (3859 pg/mL). CMT1A patients with mild or moderate severity (CMTNSv2 < 20) showed higher levels of plasma NCAM1 than healthy controls. Immunofluorescent NCAM1 staining for the sural nerves of CMT patients showed that NCAM1‐positive onion bulb cells and possible demyelinating Schwann cells might be associated with the specific increase of plasma NCAM1 in demyelinating CMT. Conclusions: The plasma NCAM1 levels in demyelinating CMT might be a surrogate biomarker reflecting pathological Schwann cell status and disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. INF2 mutations in patients with a broad phenotypic spectrum of Charcot‐Marie‐Tooth disease and focal segmental glomerulosclerosis.
- Author
-
Park, Jin Hee, Kwon, Hye Mi, Nam, Da Eun, Kim, Hye Jin, Nam, Soo Hyun, Kim, Sang Beom, Choi, Byung‐Ok, and Chung, Ki Wha
- Subjects
GENETIC mutation ,MICROFILAMENT proteins ,CHARCOT-Marie-Tooth disease ,DESCRIPTIVE statistics ,DATA analysis software ,FOCAL segmental glomerulosclerosis ,PHENOTYPES ,LONGITUDINAL method - Abstract
Mutations in INF2 are associated with the complex symptoms of Charcot‐Marie‐Tooth disease (CMT) and focal segmental glomerulosclerosis (FSGS). To date, more than 100 and 30 genes have been reported to cause these disorders, respectively. This study aimed to identify INF2 mutations in Korean patients with CMT. This study was conducted with 743 Korean families with CMT who were negative for PMP22 duplication. In addition, a family with FSGS was included in this study. INF2 mutations were screened using whole exome sequencing (WES) and filtering processes. As the results, four pathogenic INF2 mutations were identified in families with different clinical phenotypes: p.L78P and p.L132P in families with symptoms of both CMT and FSGS; p.C104Y in a family with CMT; and p.R218Q in a family with FSGS. Moreover, different CMT types were observed in families with CMT symptoms: CMT1 in two families and Int‐CMT in another family. Hearing loss was observed in two families with CMT1. Pathogenicity was predicted by in silico analyses, and considerable conformational changes were predicted in the mutant proteins. Two mutations (p.L78P and p.C104Y) were unreported, and three families showed de novo mutations that were putatively occurred from fathers. This study suggests that patients with INF2 mutations show a broad phenotypic spectrum: CMT1, CMT1 + FSGS, CMTDIE + FSGS, and FSGS. Therefore, the genotype‐phenotype correlation may be more complex than previously recognized. We believe that this study expands the clinical spectrum of patients with INF2 mutations and will be helpful in the molecular diagnosis of CMT and FSGS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Variants of aminoacyl‐tRNA synthetase genes in Charcot‐Marie‐Tooth disease: A Korean cohort study.
- Author
-
Nam, Da Eun, Park, Jin Hee, Park, Cho Eun, Jung, Na Young, Nam, Soo Hyun, Kwon, Hye Mi, Kim, Hyun Su, Kim, Sang Beom, Son, Won Seok, Choi, Byung‐Ok, and Chung, Ki Wha
- Subjects
TRANSFER RNA ,GENETIC mutation ,CHARCOT-Marie-Tooth disease ,DESCRIPTIVE statistics - Abstract
Charcot‐Marie‐Tooth disease (CMT) and related diseases are a genetically and clinically heterogeneous group of peripheral neuropathies. Particularly, mutations in several aminoacyl‐tRNA synthetase (ARS) genes have been reported to cause axonal CMT (CMT2) or distal hereditary motor neuropathy (dHMN). However, the common pathogenesis among CMT subtypes by different ARS gene defects is not well understood. This study was performed to investigate ARS gene mutations in a CMT cohort of 710 Korean families. Whole‐exome sequencing was applied to 710 CMT patients who were negative for PMP22 duplication. We identified 12 disease‐causing variants (from 13 families) in GARS1, AARS1, HARS1, WARS1, and YARS1 genes. Seven variants were determined to be novel. The frequency of overall ARS gene mutations was 1.22% among all independent patients diagnosed with CMT and 1.83% in patients negative for PMP22 duplication. WARS1 mutations have been reported to cause dHMN; however, in our patients with WARS1 variants, CMT was associated with sensory involvement. We analyzed genotype‐phenotype correlations and expanded the phenotypic spectrum of patients with CMT possessing ARS gene variants. We also characterized clinical phenotypes according to ARS genes. This study will be useful for performing exact molecular and clinical diagnoses and providing reference data for other population studies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. HDAC6 Inhibition Corrects Electrophysiological and Axonal Transport Deficits in a Human Stem Cell‐Based Model of Charcot‐Marie‐Tooth Disease (Type 2D).
- Author
-
Smith, Alec S.T., Kim, Jong Hyun, Chun, Changho, Gharai, Ava, Moon, Hyo Won, Kim, Eun Young, Nam, Soo Hyun, Ha, Nina, Song, Ju Young, Chung, Ki Wha, Doo, Hyun Myung, Hesson, Jennifer, Mathieu, Julie, Bothwell, Mark, Choi, Byung‐Ok, and Kim, Deok‐Ho
- Subjects
CHARCOT-Marie-Tooth disease ,AXONAL transport ,TRANSFER RNA ,INDUCED pluripotent stem cells ,ELECTROPHYSIOLOGY ,HISTONE deacetylase inhibitors - Abstract
Charcot‐Marie‐Tooth disease type 2D (CMT2D), is a hereditary peripheral neuropathy caused by mutations in the gene encoding glycyl‐tRNA synthetase (GARS1). Here, human induced pluripotent stem cell (hiPSC)‐based models of CMT2D bearing mutations in GARS1 and their use for the identification of predictive biomarkers amenable to therapeutic efficacy screening is described. Cultures containing spinal cord motor neurons generated from this line exhibit network activity marked by significant deficiencies in spontaneous action potential firing and burst fire behavior. This result matches clinical data collected from a patient bearing a GARS1P724H mutation and is coupled with significant decreases in acetylated α‐tubulin levels and mitochondrial movement within axons. Treatment with histone deacetylase 6 inhibitors, tubastatin A and CKD504, improves mitochondrial movement and α‐tubulin acetylation in these cells. Furthermore, CKD504 treatment enhances population‐level electrophysiological activity, highlighting its potential as an effective treatment for CMT2D. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Phenotypic heterogeneity in patients with NEFL‐related Charcot–Marie–Tooth disease.
- Author
-
Kim, Hye Jin, Kim, Sang Beom, Kim, Hyun Su, Kwon, Hye Mi, Park, Jae Hong, Lee, Ah Jin, Lim, Si On, Nam, Soo Hyun, Hong, Young Bin, Chung, Ki Wha, and Choi, Byung‐Ok
- Subjects
CHARCOT-Marie-Tooth disease ,VISUAL evoked potentials ,PHENOTYPES ,HETEROGENEITY ,HEARING disorders - Abstract
Charcot–Marie–Tooth disease (CMT) is the most common hereditary peripheral neuropathy. Mutations in the neurofilament light polypeptide (NEFL) gene produce diverse clinical phenotypes, including demyelinating (CMT1F), axonal (CMT2E), and intermediate (CMTDIG) neuropathies. From 2005 to 2020, 1,143 Korean CMT families underwent gene sequencing, and we investigated the clinical, genetic, and neuroimaging spectra of NEFL‐related CMT patients. Ten NEFL mutations in 17 families (1.49%) were identified, of which three (p.L312P, p.Y443N, and p.K467N) were novel. Eight de novo cases were identified at a rate of 0.47 based on a cosegregation analysis. The age of onset was ≤3 years in five cases (13.5%). The patients revealed additional features including delayed walking, ataxia, dysphagia, dysarthria, dementia, ptosis, waddling gait, tremor, hearing loss, and abnormal visual evoked potential. Signs of ataxia were found in 26 patients (70.3%). In leg MRI analyses, various degrees of intramuscular fat infiltration were found. All compartments were evenly affected in CMT1F patients. The anterior and anterolateral compartments were affected in CMT2E, and the posterior compartment was affected in CMTDIG. Thus, NEFL‐related CMT patients showed phenotypic heterogeneities. This study's clinical, genetic, and neuroimaging results could be helpful in the evaluation of novel NEFL variants and differential diagnosis against other CMT subtypes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Genetic and clinical spectrums in Korean Charcot‐Marie‐Tooth disease patients with myelin protein zero mutations.
- Author
-
Kim, Hye Jin, Nam, Soo Hyun, Kwon, Hye Mi, Lim, Si On, Park, Jae Hong, Kim, Hyun Su, Kim, Sang Beom, Lee, Kyung Suk, Lee, Ji Eun, Choi, Byung‐Ok, and Chung, Ki Wha
- Subjects
- *
CHARCOT-Marie-Tooth disease , *MYELIN proteins , *MEMBRANE proteins , *SCHWANN cells , *MUSCLE weakness , *ETHNIC groups - Abstract
Background: Charcot‐Marie‐Tooth disease (CMT) is the most common disorder of inherited peripheral neuropathies characterized by distal muscle weakness and sensory loss. CMT is usually classified into three types, demyelinating, axonal, and intermediate neuropathies. Mutations in myelin protein zero (MPZ) gene which encodes a transmembrane protein of the Schwann cells as a major component of peripheral myelin have been reported to cause various type of CMT. Methods: This study screened MPZ mutations in Korean CMT patients (1,121 families) by whole exome sequencing and targeted sequencing. Results: We identified 22 pathogenic or likely pathogenic MPZ mutations in 36 families as the underlying cause of the CMT1B, CMTDID, or CMT2I subtypes. Among them, five mutations were novel. The frequency of CMT patients with the MPZ mutations was similar or slightly lower compared to other ethnic groups. Conclusions: We showed that the median onset ages and clinical phenotypes varied by subtypes: the most severe in the CMT1B group, and the mildest in the CMT2I group. This study also observed a clear correlation that earlier onsets cause more severe symptoms. We believe that this study will provide useful reference data for genetic and clinical information on CMT patients with MPZ mutations in Korea. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A.
- Author
-
Ha, Nina, Choi, Young Il, Jung, Namhee, Song, Ju Young, Bae, Dae Kwon, Kim, Min Cheol, Lee, Yong Jae, Song, Hyeseung, Kwak, Geon, Jeong, Soyeon, Park, Saeyoung, Nam, Soo Hyun, Jung, Sung‐Chul, Choi, Byung‐Ok, Jung, Sung-Chul, and Choi, Byung-Ok
- Subjects
CHARCOT-Marie-Tooth disease ,HISTONE deacetylase inhibitors ,SCIATIC nerve ,MYELINATION ,SCHWANN cells ,TREATMENT effectiveness ,MYELIN sheath ,RESEARCH ,NERVE tissue proteins ,ANIMAL experimentation ,RESEARCH methodology ,PERIPHERAL nervous system ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding ,MICE - Abstract
Background and Purpose: Charcot-Marie-Tooth (CMT) disease is the most common hereditary peripheral neuropathy. CMT type 1A (CMT1A) accounts for approximately 50% of CMT patients and is linked to PMP22 gene duplication. Histone deacetylase-6 (HDAC6) has pleiotropic effects, such as regulating lipid homeostasis and cellular stress. Although HDAC6 has been regarded as a promising drug target for neurodegenerative diseases, its inhibition has not yet been tested in CMT1A. Here we have tested the therapeutic potential of CKD-504, a clinical stage HDAC6 inhibitor, in a mouse model of CMT1A EXPERIMENTAL APPROACH: The potency and selectivity of CKD-504 was evaluated, using a HDAC enzyme panel assay and western blots. The therapeutic potential of CKD-504 was evaluated using behavioural testing and electrophysiological assessments in the C22 mouse model of CMT1A. PMP22 protein expression and aggregation were analysed in mesenchymal stem cell-derived Schwann cells from CMT1A patients and sciatic nerves from C22 mice.Key Results: The HDAC6 inhibitor, CKD-504, modulated molecular chaperon proteins such as HSP90 and HSP70, which are involved in the folding/refolding of proteins such as PMP22. CKD-504 treatment restored myelination in both mesenchymal stem cell-derived Schwann cells from CMT1A patients and sciatic nerves of C22 mice and improved the axonal integrity of the sciatic nerve, leading to behavioural, electrophysiological, and histological improvements in C22 mice.Conclusion and Implications: A novel HDAC6 inhibitor, CKD-504, has potent therapeutic efficacy for CMT1A. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
9. p75 and neural cell adhesion molecule 1 can identify pathologic Schwann cells in peripheral neuropathies.
- Author
-
Kim, Young Hee, Kim, Young Hye, Shin, Yoon Kyung, Jo, Young Rae, Park, Da Kyeong, Song, Min‐Young, Yoon, Byeol‐A., Nam, Soo Hyun, Kim, Jong Hyun, Choi, Byung‐Ok, Shin, Ha Young, Kim, Seung Woo, Kim, Se Hoon, Hong, Young Bin, Kim, Jong Kuk, and Park, Hwan Tae
- Subjects
NEURAL cell adhesion molecule ,SCHWANN cells ,CELL adhesion molecules ,NEUROTROPHINS ,NEUROTROPHIN receptors ,ENZYME-linked immunosorbent assay ,NEURODEGENERATION - Abstract
Objective: Myelinated Schwann cells (SCs) in adult peripheral nerves dedifferentiate into immature cells in demyelinating neuropathies and Wallerian degeneration. This plastic SC change is actively involved in the myelin destruction and clearance as demyelinating SCs (DSCs). In inherited demyelinating neuropathy, pathologically differentiated and dysmyelinated SCs constitute the main nerve pathology. Methods: We investigated whether this SC plastic status in human neuropathic nerves could be determined by patient sera to develop disease‐relevant serum biomarkers. Based on proteomics analysis of the secreted exosomes from immature SCs, we traced p75 neurotrophin receptor (p75) and neural cell adhesion molecule 1 (NCAM) in the sera of patients with peripheral neuropathy. Results: Enzyme‐linked immunosorbent assay (ELISA) revealed that p75 and NCAM were subtype‐specifically expressed in the sera of patients with peripheral neuropathy. In conjunction with these ELISA data, pathological analyses of animal models and human specimens suggested that the presence of DSCs in inflammatory neuropathy and of supernumerary nonmyelinating or dysmyelinating SCs in inherited neuropathy could potentially be distinguished by comparing the expression profiles of p75 and NCAM. Interpretation: This study indicates that the identification of disease‐specific pathological SC stages might be a valuable tool for differential diagnosis of peripheral neuropathies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Axonal Charcot-Marie-Tooth neuropathy concurrent with distal and proximal weakness by translational elongation of the 3′ UTR in NEFH.
- Author
-
Nam, Da Eun, Jung, Sung‐Chul, Yoo, Da Hye, Choi, Sun Seong, Seo, Sung‐Yum, Kim, Gwang Hoon, Kim, Song Ja, Nam, Soo Hyun, Choi, Byung‐Ok, and Chung, Ki Wha
- Subjects
AMYOTROPHIC lateral sclerosis ,PERIPHERAL neuropathy diagnosis ,MEDIAN nerve ,CHARCOT-Marie-Tooth disease ,GENES ,GENETIC counseling ,MAGNETIC resonance imaging ,GENETIC mutation ,PROTEINS ,ULNAR nerve ,MUSCLE weakness ,SYMPTOMS ,ANATOMY ,DISEASE risk factors - Abstract
Mutations in the NEFH gene encoding the heavy neurofilament protein are usually associated with neuronal damage and susceptibility to amyotrophic lateral sclerosis (ALS). Recently, frameshift variants in NEFH (p.Asp1004Glnfs*58 and p.Pro1008Alafs*56) have been reported to be the underlying cause of axonal Charcot-Marie-Tooth disease type 2CC (CMT2CC). The frameshift mutation resulted in a stop loss and translation of a cryptic amyloidogenic element (CAE) encoded by the 3′ untranslated region (UTR). This study also identified a de novo c.3015_3027dup frameshift mutation predicting p.Lys1010Glnfs*57 in NEFH from a CMT2 family with an atypical clinical symptom of prominent proximal weakness. This mutation is located near the previously reported frameshift mutations, suggesting a mutational hotspot. Lower limb magnetic resonance imaging (MRI) revealed marked hyperintense signal changes in the thigh muscles compared with those in the calf muscles. Therefore, this study suggests that the stop loss and translational elongations by the 3′ UTR of the NEFH mutations may be a relatively frequent genetic cause of axonal peripheral neuropathy with the specific characteristics of proximal dominant weakness. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.